ICU Medical (NASDAQ:ICUI) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “ICU Medical, Inc. develops, manufactures and sells innovative medical devices used in vascular therapy, oncology and critical care applications. They are one of the world’s leading pure-play infusion therapy companies, with global operations and a wide-ranging product portfolio that includes IV solutions, IV smart pumps, dedicated and non-dedicated IV sets and needlefree connectors, along with pain management and safety software technology designed to help meet clinical, safety and workflow goals. In addition, they manufacture automated pharmacy IV compounding systems with workflow technology, closed systems transfer devices for hazardous IV drugs, and cardiac monitoring systems to optimize patient fluid levels. “

Separately, KeyCorp initiated coverage on shares of ICU Medical in a research note on Tuesday, October 17th. They set a “sector weight” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. ICU Medical currently has an average rating of “Hold” and an average target price of $232.00.

ICU Medical (NASDAQ ICUI) opened at $222.15 on Wednesday. ICU Medical has a 52 week low of $131.35 and a 52 week high of $225.38. The company has a current ratio of 4.65, a quick ratio of 3.01 and a debt-to-equity ratio of 0.07. The company has a market cap of $4,450.00, a price-to-earnings ratio of 145.20, a price-to-earnings-growth ratio of 2.43 and a beta of 0.36.

ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, November 9th. The medical instruments supplier reported $1.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.35. ICU Medical had a net margin of 2.79% and a return on equity of 4.81%. The firm had revenue of $343.20 million for the quarter, compared to the consensus estimate of $328.56 million. During the same period in the prior year, the firm posted $1.35 EPS. The firm’s revenue was up 253.5% compared to the same quarter last year. equities research analysts predict that ICU Medical will post 3.95 earnings per share for the current fiscal year.

In other ICU Medical news, Director George A. Lopez sold 5,000 shares of the stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $205.83, for a total transaction of $1,029,150.00. Following the sale, the director now directly owns 573,916 shares of the company’s stock, valued at $118,129,130.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Scott E. Lamb sold 23,624 shares of the stock in a transaction on Thursday, January 4th. The stock was sold at an average price of $220.00, for a total transaction of $5,197,280.00. Following the sale, the chief financial officer now directly owns 29,723 shares in the company, valued at $6,539,060. The disclosure for this sale can be found here. Insiders have sold a total of 129,419 shares of company stock worth $25,454,700 over the last quarter. 13.60% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of the business. Pura Vida Investments LLC raised its holdings in shares of ICU Medical by 27.8% during the third quarter. Pura Vida Investments LLC now owns 57,500 shares of the medical instruments supplier’s stock worth $10,686,000 after purchasing an additional 12,500 shares during the period. California Public Employees Retirement System raised its holdings in shares of ICU Medical by 5.8% during the third quarter. California Public Employees Retirement System now owns 28,342 shares of the medical instruments supplier’s stock worth $5,267,000 after purchasing an additional 1,542 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of ICU Medical during the third quarter worth $572,000. Point72 Asset Management L.P. acquired a new stake in shares of ICU Medical during the third quarter worth $22,246,000. Finally, Janus Henderson Group PLC raised its holdings in shares of ICU Medical by 17.6% during the third quarter. Janus Henderson Group PLC now owns 1,684,094 shares of the medical instruments supplier’s stock worth $312,989,000 after purchasing an additional 251,793 shares during the period. 78.13% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “ICU Medical (ICUI) Rating Lowered to Hold at Zacks Investment Research” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/icu-medical-icui-rating-lowered-to-hold-at-zacks-investment-research/1800540.html.

About ICU Medical

ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.

Get a free copy of the Zacks research report on ICU Medical (ICUI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.